12-Mar-2025 10:06 AM CST - Yahoo Finance Truist remains bullish on Labcorp after 'another nice strategic acquisition' Truist analyst David MacDonald notes Labcorp (LH) announced that the company has reached an agreement to acquire oncology-focused lab testing assets from BioReference Health (OPK) for $192.5M, with an additional earnout of up to $32.
6-Mar-2025 3:00 AM CST - Yahoo Finance UK 3 Reasons to Avoid LH and 1 Stock to Buy Instead Labcorp has been a great trade, beating the S&P 500 by 6.9%. Its stock price has climbed to $255.01, representing a healthy 13.9% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
4-Mar-2025 12:11 PM CST - MSN Citigroup Upgrades Labcorp Holdings (LH) Fintel reports that on March 4, 2025, Citigroup upgraded their outlook for Labcorp Holdings (NYSE:LH) from Neutral to Buy. Analyst Price Forecast Suggests 8.66% Upside As of February 19, 2025, the average one-year price target for Labcorp Holdings is $276.
4-Mar-2025 4:26 AM CST - Business Insider Labcorp upgraded to Buy from Neutral at Citi Citi upgraded Labcorp (LH) to Buy from Neutral with a price target of $300, up from $250. Utilization rates have been running high
12-Mar-2025 10:06 AM CST - Yahoo Finance Truist remains bullish on Labcorp after 'another nice strategic acquisition' Truist analyst David MacDonald notes Labcorp (LH) announced that the company has reached an agreement to acquire oncology-focused lab testing assets from BioReference Health (OPK) for $192.5M, with an additional earnout of up to $32.
6-Mar-2025 3:00 AM CST - Yahoo Finance UK 3 Reasons to Avoid LH and 1 Stock to Buy Instead Labcorp has been a great trade, beating the S&P 500 by 6.9%. Its stock price has climbed to $255.01, representing a healthy 13.9% increase. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
4-Mar-2025 12:11 PM CST - MSN Citigroup Upgrades Labcorp Holdings (LH) Fintel reports that on March 4, 2025, Citigroup upgraded their outlook for Labcorp Holdings (NYSE:LH) from Neutral to Buy. Analyst Price Forecast Suggests 8.66% Upside As of February 19, 2025, the average one-year price target for Labcorp Holdings is $276.
4-Mar-2025 4:26 AM CST - Business Insider Labcorp upgraded to Buy from Neutral at Citi Citi upgraded Labcorp (LH) to Buy from Neutral with a price target of $300, up from $250. Utilization rates have been running high
